Switch theme
Sign up to access all valuation multiples
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, medical and dental equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics; wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory equipment, cosmetic; wholesale trade in pharmaceuticals; laboratory testing services, health support service activities, research and development, periodic inspection services, and many more activities.
1976
1.7K+
Last FY Revenue $128M
Last FY EBITDA $15.1M
$94.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Darya-Varia Laboratoria achieved revenue of $128M and an EBITDA of $15.1M.
Darya-Varia Laboratoria expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Darya-Varia Laboratoria valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $128M | XXX | XXX | XXX |
| Gross Profit | XXX | $67.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 53% | XXX | XXX | XXX |
| EBITDA | XXX | $15.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $12.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 9% | XXX | XXX | XXX |
| Net Profit | XXX | $9.6M | XXX | XXX | XXX |
| Net Margin | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Darya-Varia Laboratoria's stock price is IDR 1700 (or $0).
Darya-Varia Laboratoria has current market cap of IDR 1.90T (or $117M), and EV of IDR 1.55T (or $94.9M).
See Darya-Varia Laboratoria trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94.9M | $117M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Darya-Varia Laboratoria has market cap of $117M and EV of $94.9M.
Darya-Varia Laboratoria's trades at 0.7x EV/Revenue multiple, and 6.3x EV/EBITDA.
Equity research analysts estimate Darya-Varia Laboratoria's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Darya-Varia Laboratoria's P/E ratio is not available.
See valuation multiples for Darya-Varia Laboratoria and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $117M | XXX | $117M | XXX | XXX | XXX |
| EV (current) | $94.9M | XXX | $94.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 7.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 12.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 6.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDarya-Varia Laboratoria's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Darya-Varia Laboratoria's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Darya-Varia Laboratoria's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Darya-Varia Laboratoria and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Darya-Varia Laboratoria acquired XXX companies to date.
Last acquisition by Darya-Varia Laboratoria was XXXXXXXX, XXXXX XXXXX XXXXXX . Darya-Varia Laboratoria acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Darya-Varia Laboratoria founded? | Darya-Varia Laboratoria was founded in 1976. |
| Where is Darya-Varia Laboratoria headquartered? | Darya-Varia Laboratoria is headquartered in Indonesia. |
| How many employees does Darya-Varia Laboratoria have? | As of today, Darya-Varia Laboratoria has 1.7K+ employees. |
| Is Darya-Varia Laboratoria publicy listed? | Yes, Darya-Varia Laboratoria is a public company listed on IDX. |
| What is the stock symbol of Darya-Varia Laboratoria? | Darya-Varia Laboratoria trades under DVLA ticker. |
| When did Darya-Varia Laboratoria go public? | Darya-Varia Laboratoria went public in 1994. |
| Who are competitors of Darya-Varia Laboratoria? | Similar companies to Darya-Varia Laboratoria include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Darya-Varia Laboratoria? | Darya-Varia Laboratoria's current market cap is $117M |
| Is Darya-Varia Laboratoria profitable? | Yes, Darya-Varia Laboratoria is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
